From: A review of the LARIAT device: insights from the cumulative clinical experience
Referenes | No. of patients with attempted ligation | No. of patients meeting clinical criteria screened | Mean age | Male (%) | AC Post-procedure | Mean/median CHADS2 Score/CHA2DS-VASC Scorea (Lip et al. 2010) | HAS-BLED Score (Lip et al. 2011) |
---|---|---|---|---|---|---|---|
Bartus et al. (2011) | 12 | 14 screened, 2 excluded: 1 due to sub-optimal anatomy by pre-procedure CT, 1 due to presence of LAA thrombus by TEE at procedure onset | 57.3 | 62 | NR | NR | NR |
Bartus et al. (2013) | 92 | 119 screened, 27 excluded: 16 due to sub-optimal anatomy by pre-procedure CT, 11 due to mobile thrombus noted by TEE at time of procedure | 62 ± 10 | 57 | Warfarin if tolerated, else aspirin mono-therapy. 55 % treated with warfarin post-procedure | 1.9 ± 0.95/2.8 ± 1.56 | 2.4 ± 1.1 |
Massumi et al. (2013) | 20 | NR | 73 ± 8 | 65 | 65 % continued on Aspirin, 20 % on clopidogrel, 5 % on dual-antiplatelet therapy with Aspirin and dypyridamole, 15 % on warfarin, 5 % on rivaroxaban, 20 % on no AC | 3.2 ± 1.2/4.8 ± 1.3 | 3.5 ± 1.0 |
Stone et al. (2013) | 27 | 42 screened, 15 excluded; no further details | 75 ± 8 | 74 | Daily aspirin in all patients, dual anti-platelet therapy in 9 patients | 3.5 ± 1.4/5.1 ± 1.5 | 4.6 ± 0.9 |
Price and Gibson (2014) | 154 | NR | 72 ± 9 | 62 | Aspirin mono-therapy 31 %, dual anti-platelet 24 %, oral AC 23 %, clopidogrel mono-therapy 7 %, aggrenox 0.6 % | 2.8 ± 1.4/4.1 ± 1.6 | 3.2 ± 1.2 |
Miller et al. (2014) | 41 | NR | 75 ± 10 | 46 | At last follow-up, Aspirin 46 %, warfarin 20 %, Plavix 7 % dabigatran 7 %, rivaroxaban 7 % | 3.0 ± 1.3 | 4.4 ± 1.4 |